

Your Abstract Submission Has Been Received

Print this page

You have submitted the following abstract to 22nd Annual John Goldman Conference on CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY. Receipt of this notice does not guarantee that your submission was complete or free of errors.

Characterization of Colombian Patients with Chronic Myeloid Leukemia: Second ACHO'S RENEHOC Report on CML.

Virginia Abello^{1,2}, Daniel Espinosa^{1,3}, Rigoberto Gomez⁴, Claudia Sossa^{5,6}, Guillermo Quintero^{7,8}, Lina María Abenosa^{7,8}, Monica Osuna⁹, Jheremy Reyes⁹, Alicia Henao¹⁰, Henry Idrobo^{11,12,13}, Juan Manuel Herrera¹⁴, Domingo Saavedra¹⁵, Kenny Galvez¹⁶ and Lina Gaviria¹⁷, (1)Hospital de San José, Bogotá, Colombia, (2)Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia, (3)Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia, (4)Instituto de Oncología - Hematoncólogos, Calí, Colombia, (5)Universidad Autonoma de Bucaramanga, Bucaramanga, Colombia, (6)Clinica FOSCAL, Floridablanca, Colombia, (7)Fundación Santa Fe, Bogotá, Colombia, (8)Universidad de los Andes, Bogotá, Colombia, (9)Clínica Nogales, Bogotá, Colombia, (10)Clínica Oncológica Astorga, Bogotá, Colombia, (11)Centro Julián Coronel, Calí, Colombia, (12)Centro Médico Imbanaco, Calí, Colombia, (13)Universidad Del Valle, Cali, Colombia, (14)Centro Medico Imbanaco, Cali, Colombia, (15)Clínica Vida, Medellin, Colombia, (16)Hospital Pablo Tobon Uribe, Medellin, Colombia, (17)San Vicente Fundación, Medellin, Colombia

Abstract Text:


There is little published information about CML treatment in Colombia. The Colombian Association of Hematology and Oncology (ACHO), has been developing a registry of hematological diseases (RENEHOC), collecting information since January 2018 at 13 centers in the main cities of the

country. Since December 2019, RENEHOC has been collecting information on CML. The aim of this second report is to characterize this population.

RENEHOC is an on-line data base, approved by an ethics committee, with a tool for data entry. This report summarizes data on CML patients as of May 2020, focused on general descriptive statistics, used to analyze patient's demographic and clinical characteristics. The Kaplan-Meier method was used to assess progression free survival (PFS) rates, defined as progression to AP/BP or dead. Hazard Ratios (HR) using Cox proportional hazards regression modeling was estimated.

A total of 271 patients have been registered. At diagnosis mean age was 54 years (19-92), 60.1% (163) were males, most patients were in chronic phase (91%) and almost 40% had high Sokal score (27% low, 34% intermediate, 39% high). Imatinib was the first line treatment in two thirds of patients (170), followed by Dasatinib (56) and Nilotinib (45). Cumulative incidence rate of response with first line treatment was: CHR 90%, MMR 66% and 4.5 MR 53%. Patients treated on first line with Dasatinib and Nilotinib, more frequently achieved <10% PCR BCR/ABL at 3 months than those treated with Imatinib (94.1%, 82%, 60% respectively). 48% required a second line (23% intolerance, 25% failure), most frequently used TKI in this setting were Dasatinib (51%) and Nilotinib (41.9%). Median follow-up was 61 months (1-204), 72% of patients were in optimal response according to ELN definitions, including 9 patients on treatment free remission (TFR). Only 7 (2.5%) patients died, all deaths were CML related. The only significant prognosis factor associated with PFS was Sokal score at diagnosis. Mean PFS was 59 months for low Sokal and 45.2 for intermediate/high ($p=0.0093$) (Figure 1).

Outcomes in this cohort appear to be comparable with other real-life population-based studies. In this group Sokal Score at diagnosis was the only significant prognosis factor. At this timepoint data from RENEHOC is still limited, however, the potential of this growing registry is evident, since information from Colombia regarding CML treatment is limited. We hope that the data collected will serve to improve the treatment of these patients in the country as more information is gathered

**Title:**

Characterization of Colombian Patients with Chronic Myeloid Leukemia: Second Aho's Renohoc Report on CML.

Submitter's E-mail Address:

virginia.abello@gmail.com

Category:

Clinical

Comments to Organizers:

Asociación Colombiana de Hematología y Oncología

First Presenting Author***Presenting Author***

Virginia Abello

Email: virginia.abello@gmail.com -- Will not be published

Hospital de San José

Bogotá
Colombia
Fundación Universitaria de Ciencias de la Salud (FUCS)
Bogotá
Colombia

Second Author

Daniel Espinosa
Email: danielEspinosa77@gmail.com -- Will not be published

Hospital de San José
Bogotá
Colombia
Fundación Universitaria de Ciencias de la Salud
Bogotá
Colombia

Third Author

Rigoberto Gomez
Email: virginia.abello@gmail.com -- Will not be published

Instituto de Oncología - Hematoncólogos
Calí
Colombia

Fourth Author

Claudia Sossa

Email: claudiasossa@gmail.com -- Will not be published

Universidad Autonoma de Bucaramanga
Bucaramanga
Colombia
Clinica FOSCAL
Floridablanca
Colombia

Fifth Author

Guillermo Quintero

Email: quiquequintero@yahoo.com.mx -- Will not be published

Fundación Santa Fe
Bogotá
Colombia
Universidad de los Andes
Bogotá
Colombia

Sixth Author

Lina María Abenosa

Email: linabenoza@gmail.com -- Will not be published

Fundación Santa Fe
Bogotá

Colombia
Universidad de los Andes
Bogotá
Colombia

Seventh Author

Monica Osuna
Email: mony_op@hotmail.com -- Will not be published

Clínica Nogales
Bogotá
Colombia

Eighth Author

Jheremy Reyes
Email: jheremyreyesmd@gmail.com -- Will not be published

Clínica Nogales
Bogotá
Colombia

Ninth Author

Alicia Henao
Email: aliciah@une.net.co -- Will not be published

Clínica Oncológica Astorga
Bogotá
Colombia

Tenth Author

Henry Idrobo
Email: henryidroboquintero@gmail.com -- Will not be published

Centro Julián Coronel
Calí
Colombia
Centro Médico Imbanaco
Calí
Colombia
Universidad Del Valle
Cali
Colombia

Eleventh Author

Juan Manuel Herrera
Email: jherrera68@gmail.com -- Will not be published

Centro Medico Imbanaco
Cali
Colombia

Twelfth Author

Domingo Saavedra

Email: jsaavedra@une.net.co -- Will not be published

Clínica Vida
Medellin
Colombia

Thirteenth Author

Kenny Galvez

Email: kennygalvez@gmail.com -- Will not be published

Hospital Pablo Tobon Uribe
Medellin
Colombia

Fourteenth Author

Lina Gaviria

Email: lina.gaviria.jllo@hotmail.com -- Will not be published

San Vicente Fundación
Medellin
Colombia

If necessary, you can make changes to your abstract submission

To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.

Or point your browser to [/esh/reminder.cgi](#) to have that URL mailed to you again. Your username/password are 19832/726687.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

[Tell us what you think of the abstract submission process](#)

[Home Page](#)